| Catalog No | Package | Original Price | Price | Inventory | Quantity | Operating |
|---|---|---|---|---|---|---|
| BP0864-20mg | 20mg | $30.00 | Sign in |
|
Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
Ligustrazine Hydrochloride (CAS number: 76494-51) is a natural derivative derived from the traditional Chinese medicine Ligusticum chuanxiong Hort. It has attracted much attention due to its significant cardiovascular protective effects. Chuanxiong, as an important traditional Chinese medicine herb for promoting blood circulation and removing blood stasis, has shown multi-target and multi mechanism therapeutic potential in modern pharmacological research with its main active ingredient, ligustrazine. Ligustrazine hydrochloride has become an important candidate molecule for developing new therapeutic drugs for cardiovascular diseases due to its good water solubility, high bioavailability, and low toxicity and side effects. This article provides a systematic review of the chemical structure and physicochemical properties, plant sources and extraction methods, pharmacological activity and mechanism of action, pharmacological evaluation, pharmacokinetic characteristics, as well as the clinical application prospects and future research directions of ligustrazine hydrochloride. The aim is to provide theoretical basis and reference for the in-depth research and clinical translation of this natural product.
The chemical name of ligustrazine hydrochloride is 2,3,5,6-tetramethylpiperazine hydrochloride, with the molecular formula C8H14N2 · HCl and a molecular weight of 136.1980. Its structural core is a piperazine ring with four methyl substituents, and its hydrochloride form gives it good water solubility (5.9652 mg/mL), which is beneficial for drug formulation development and in vivo absorption. The LogP value is 1.8234, indicating that it has moderate lipophilicity and is conducive to penetrating cell membranes and the blood-brain barrier (BBB). Its TPSA (topological polar surface area) is 25.78 Å ², further supporting its good membrane permeability. It is worth noting that ligustrazine hydrochloride does not exhibit hERG channel inhibitory activity, indicating a low risk of cardiac toxicity. The Ames test result is 0.0, indicating no significant mutagenicity and high safety.
The parent compound of ligustrazine hydrochloride, ligustrazine, mainly exists in the rhizome of Ligusticum chuanxiong. Chuanxiong is the dried rhizome of Ligusticum chuanxiong Hort., a plant in the Umbelliferae family, widely distributed in Sichuan, Yunnan, and other regions of China. Traditional extraction methods often use water extraction or alcohol extraction combined with acid-base adjustment to obtain crude extracts of ligustrazine. In modern technology, ultrasound assisted extraction, microwave-assisted extraction, and column chromatography purification techniques are widely used to improve extraction efficiency and purity.
The specific process usually includes: drying and crushing of Ligusticum chuanxiong, extraction with ethanol or methanol, promoting the formation of Ligusticum chuanxiong hydrochloride under acidic conditions, followed by purification through steps such as activated carbon decolorization and silica gel column chromatography, and finally obtaining Ligusticum chuanxiong hydrochloride crystals. In recent years, the development of green solvents and continuous flow extraction technology has further optimized the extraction process, improved yield and environmental friendliness.
The pharmacological activity of ligustrazine hydrochloride in the cardiovascular system has been extensively validated through in vitro and in vivo experiments, mainly manifested as multiple effects such as anti ischemia-reperfusion injury, vasodilation, antiplatelet aggregation, anti-inflammatory, and antioxidant.
Anti myocardial ischemia-reperfusion injury
Ligustrazine hydrochloride can significantly reduce myocardial cell apoptosis and inflammatory response caused by myocardial ischemia-reperfusion, improve myocardial tissue microcirculation, and reduce myocardial infarction area. Animal models have shown that it exerts cardioprotective effects by regulating oxidative stress levels and inhibiting the release of inflammatory mediators.
Expanding blood vessels and improving microcirculation
Ligustrazine hydrochloride can promote the production of nitric oxide (NO), activate endothelial cells, dilate coronary arteries and surrounding blood vessels, and improve hemodynamics. Its vasodilatory effect helps to lower blood pressure and improve tissue perfusion.
Antiplatelet aggregation and antithrombotic formation
This compound can inhibit platelet activation and aggregation, reduce the risk of thrombosis, and is suitable for the prevention and treatment of ischemic cardiovascular and cerebrovascular diseases.
Anti inflammatory and antioxidant effects
Ligustrazine hydrochloride reduces the inflammatory response of vascular endothelial cells by inhibiting the expression of inflammatory factors such as ICAM-1 and VCAM-1; Simultaneously clearing free radicals, reducing oxidative stress damage, and protecting the cardiovascular system.
The multi-target mechanism of action of ligustrazine hydrochloride is the basis of its cardiovascular protective effect. Through molecular biology techniques and network pharmacology analysis, multiple key targets have been identified:
The synergistic regulation of these targets enables ligustrazine hydrochloride to exert multidimensional protective effects in the pathological process of cardiovascular disease.
Ligustrazine hydrochloride has good pharmacological parameters. The moderate molecular weight (136.2 Da) and LogP (1.82) comply with Lipinski's rule, indicating good oral bioavailability. The low TPSA value is beneficial for cell membrane penetration and blood-brain barrier permeability, supporting its potential application in central nervous system related cardiovascular diseases.
Toxicological evaluation shows that ligustrazine hydrochloride has no significant hERG channel inhibitory effect and reduces the risk of arrhythmia. Ames test negative, indicating no mutagenicity and high safety.
Pharmacokinetic studies have shown that ligustrazine hydrochloride is rapidly absorbed after oral administration, with a moderate plasma half-life and wide distribution, especially effective in penetrating the blood-brain barrier. Its main metabolic pathway is hepatic enzymatic metabolism, and the metabolites have no significant toxicity. Excretion is mainly completed through the kidneys, and the risk of accumulation in the body is relatively low.
Ligustrazine hydrochloride, as a natural product derivative with multiple targets and mechanisms, has shown broad application prospects in the field of cardiovascular disease prevention and treatment. Preliminary clinical studies have confirmed its efficacy in diseases such as coronary heart disease, cerebral ischemia, and myocardial ischemia-reperfusion injury, with mild side effects and good tolerability.
In the future, with the development of precision medicine, ligustrazine hydrochloride can be combined with genomics and metabolomics methods to further clarify the indications and medication plans for personalized treatment. Meanwhile, research based on nanotechnology and novel drug delivery systems is expected to enhance their bioavailability and targeting, and improve therapeutic efficacy.
In addition, the potential applications of ligustrazine hydrochloride in neuroprotection, anti-inflammatory, and antioxidant fields are also worth exploring, especially in the recovery of neurological function after stroke and the comprehensive management of chronic cardiovascular and cerebrovascular diseases, which may play an important role.
Ligustrazine hydrochloride, as a natural derivative derived from the traditional Chinese medicine Chuanxiong, exhibits significant cardiovascular protective effects due to its unique chemical structure and excellent physicochemical properties. Its multi-target and multi mechanism pharmacological activity provides new ideas and strategies for the prevention and treatment of cardiovascular diseases. The excellent drug properties and high safety make it a powerful candidate molecule for the development of cardiovascular drugs. In the future, through in-depth molecular mechanism research, optimization of drug formulations, and large-scale clinical trials, ligustrazine hydrochloride is expected to achieve wider clinical applications and benefit a large number of patients.
